Physician profile
Eugene Lowry
NPI 1518384684
$921.68
in general payments reported to CMS, 2019-2025
13 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $94.01 · 2021: $39.87 · 2022: $132 · 2023: $90.89 · 2024: $136 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $169.19 | 2020-2024 | |
| Aerie Pharmaceuticals, INC. | $151.23 | 2019-2020 | |
| Alcon Vision LLC | $124.98 | 2022-2025 | Clareon |
| Allergan, INC. | $101.12 | 2019 | |
| Oyster Point Pharma, INC. | $53.85 | 2023 | Tyrvaya |
| Abbvie INC. | $50.82 | 2025 | |
| Novartis Pharmaceuticals Corporation | $46.17 | 2020-2023 | |
| Thea Pharma INC. | $44.31 | 2024 | Iyuzeh |
| Sight Sciences, INC. | $43.41 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Kala Pharmaceuticals, INC. | $37.58 | 2019 | |
| Glaukos Corporation | $36.40 | 2025 | Istent Infinite, Idosetr |
| Sun Pharmaceutical Industries INC. | $36.35 | 2023-2024 | Cequa |
| Harrow Eye, LLC | $26.27 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Lowry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.